Patents Examined by Joseph A. Lipovsky
  • Patent number: 5017609
    Abstract: A pharmaceutical composition is disclosed, which contains a short-acting .beta.-blocking compound of the formula ##STR1## wherein R.sub.1 may be an alkyl, cycloalkyl, alkenyl, alkynyl, alkyl carboxymethyl, aryl carboxymethyl, aryl or aralkyl, A may be an alkylene or alkenylene, X may be independently amino, hydrogen, halogen, hydroxy, alkoxy, aryloxy, aralkyl, cyano, amido or trifluoromethyl, n is an integer from 1 to about 4, R may be an alkyl, propargyl, dimethylpropargyl or hydroxyalkyl; or a pharmaceutically acceptable salt thereof in a hydroalcoholic solution further containing a physiologically acceptable buffering agent, ethanol and a physiologically acceptable liquid polyhydric compound. A method for treatment or prophylaxis of cardiac disorders using the composition of the present invention is also disclosed.
    Type: Grant
    Filed: November 16, 1989
    Date of Patent: May 21, 1991
    Assignee: E. I. Du Pont de Nemours and Company
    Inventors: Agustin Escobar, Dietmar Wagenknecht, Ahmad W. Malick
  • Patent number: 4985461
    Abstract: This invention relates to insecticidal compositions containing N'-substituted-N,N'-diacylhydrazines, methods of using such compositions and certain novel insecticidal N'-substituted-N,N'-diacylhydrazines.
    Type: Grant
    Filed: October 21, 1985
    Date of Patent: January 15, 1991
    Assignee: Rohm and Haas Company
    Inventors: Adam C. Hsu, Harold E. Aller
  • Patent number: 4981683
    Abstract: Solid dihydropyridines, e.g. nifedipine and nimodipine preparations having a maximum standard deviation of the active compound content of 3% contain 1 part by weight of nifedipine, 2 to 6 parts by weight of PVP with a mean molecular weight of 15,000 to 50,000, 3.5 to 15 parts by weight of cellulose, 0.25 to 4 parts by weight of starch and 0.5 to 4 parts by weight of cross-linked insoluble PVPP, and, if appropriate, one or more further pharmaceutical auxiliaries and excipients. These preparations show a good release of dihydropyridine with good content uniformity.
    Type: Grant
    Filed: May 23, 1989
    Date of Patent: January 1, 1991
    Assignee: Bayer Aktiengesellschaft
    Inventor: Ahmed Hegasy
  • Patent number: 4978657
    Abstract: Novel 19-nor-steroids of the formula ##STR1## wherein R.sub.1 is an organic group of 1 to 18 carbon atoms optionally containing at leat one heteroatom with the atom immediately adjacent the 11-carbon atom being carbon, R.sub.2 is a hydrocarbon of 1 to 8 carbon atoms, X is the remainder of a pentagonal or hexagonal ring optionally substituted and optionally containing one unsaturated bond, the A and B rings are selected from the group consisting of ##STR2## R' and R" are individually selected from the group consisting of hydrogen, --CN and alkyl of 1 to 4 carbon atoms, R.sub.x is selected from the group consisting of hydrogen and OR.sub.e, R.sub.e is selected from the group consisting of hydrogen, optionally substituted alkyl of 1 to 6 carbon atoms and acyl, R.sub.a may be in the E or Z positions as indicated by the wavy line and is selected from the group consisting of ##STR3## and acyloxy, R.sub.a ' and R.sub.
    Type: Grant
    Filed: December 17, 1985
    Date of Patent: December 18, 1990
    Assignee: Roussel Uclaf
    Inventors: Jean-Georges Teutsch, Vesperto Torelli, Roger Deraedt, Daniel Philibert, Germain Costerousse
  • Patent number: 4978681
    Abstract: A hair-growing agent which exhibits a strong hair-growing effect. The hair-growing agent according to the present invention contains as an effective ingredient an aliphatic carboxylic acid having an odd number of carbon atoms or a derivative thereof.
    Type: Grant
    Filed: August 16, 1988
    Date of Patent: December 18, 1990
    Assignee: Lion Corporation
    Inventors: Kuniaki Adachi, Hideo Tamai, Masanao Sadai
  • Patent number: 4978658
    Abstract: A composition for in vivo inhibition of aromatase in a mammal, which comprises an in vivo inhibitory amount of a compound having the following general formula: ##STR1## wherein R.sub.1 is hydrogen or C.sub.1-4 acyl, in combination with as pharmaceutically acceptable carrier or diluent thereof.
    Type: Grant
    Filed: October 14, 1988
    Date of Patent: December 18, 1990
    Assignee: Medical Foundation of Buffalo, Inc.
    Inventor: Yoshio Osawa
  • Patent number: 4973721
    Abstract: Novel Vitamin D.sub.3 derivatives of the following formula ##STR1## wherein R represents a hydrogen atom or a lower alkyl group. These compounds have an activity of inducing differentiation of tumor cells, and are useful for anti-tumor agents. On the other hand, the compounds have almost no vitamin D activity.
    Type: Grant
    Filed: October 12, 1989
    Date of Patent: November 27, 1990
    Assignee: Yamanouchi Pharmaceutical Co., Ltd.
    Inventors: Nobuo Ikekawa, Tadashi Eguchi
  • Patent number: 4970237
    Abstract: This invention relates to the use of clomiphene in preventing osteoporosis in humans and treating human patients experiencing osteoporosis.
    Type: Grant
    Filed: February 14, 1989
    Date of Patent: November 13, 1990
    Assignee: Yale University
    Inventors: Pamela S. Jensen, Florence Comite
  • Patent number: 4970205
    Abstract: Invented are sulfonic acid substituted analogues of steroidal synthetic compounds, pharmaceutical compositions containing these compounds, and methods of using these compounds to inhibit steroid 5-.alpha.-reductase, including using these compounds to reduce or maintain prostate size. Also invented are intermediates used in preparing these compounds.
    Type: Grant
    Filed: December 23, 1988
    Date of Patent: November 13, 1990
    Assignee: SmithKline Beecham Corporation
    Inventors: Dennis A. Holt, Mark A. Levy, Brian W. Metcalf
  • Patent number: 4968675
    Abstract: 16.alpha.-Methyl-21-[4-[2,6-bis(1-pyrrolidinyl)-4-pyrimidinyl]-1-piperaziny l]pregna-1,4,9(11)-triene-3,20-dione monomethanesulfonate causes hemolysis when injected. However, when formulated with a citric acid/sodium citrate both the hemolysis and hypotension side effects are prevented.
    Type: Grant
    Filed: October 28, 1988
    Date of Patent: November 6, 1990
    Assignee: Upjohn
    Inventors: Ching-Chiang Su, Teresa Harshman
  • Patent number: 4968822
    Abstract: A 21-alkoxysteroid compound represented by the formula ##STR1## wherein R.sup.1 is an alkyl group having 1 to 4 carbon atoms or a methylthiomethyl group, R.sup.2 is an alkanoyl group having 2 to 7 carbon atoms, and a wavy line indicates the .alpha.- or .beta.-configuration has anti-inflammatory activity.
    Type: Grant
    Filed: December 5, 1988
    Date of Patent: November 6, 1990
    Assignee: Taisho Pharmaceutical Co., Ltd.
    Inventors: Morihiro Mitsukuchi, Tomoyuki Ikemoto, Minoru Taguchi, Katsuo Hatayama, Kaoru Sota
  • Patent number: 4966898
    Abstract: This invention is directed to 4-substituted 17.beta.-(cyclopropylamino)androst-5-en-3.beta.-ol and related compounds and also to a method for using such compounds in the treatment of androgen-dependent disorders. The compounds are prepared by the hydride reduction of an appropriate steroidal imine or enamine.
    Type: Grant
    Filed: August 15, 1989
    Date of Patent: October 30, 1990
    Assignee: Merrell Dow Pharmaceuticals Inc.
    Inventors: Michael R. Angelastro, Thomas R. Blohm
  • Patent number: 4963540
    Abstract: A pharmaceutical composition suitable for oral administration comprises micronized progesterone in an oil vehicle which is high in glycerides of polyunsaturated fatty acids. Micronized progesterone particles suspended in such an oil vehicle are absorbed more readily into the bloodstream and achieve high progesterone blood serum levels. The pharmaceutical composition according to the invention can be readily formulated into capsules and administered for the treatment of premenstrual syndrome.
    Type: Grant
    Filed: January 13, 1988
    Date of Patent: October 16, 1990
    Inventors: Wayne S. Maxson, Joel T. Hargrove, Philip G. Meyers
  • Patent number: 4962098
    Abstract: Contraceptive methods and delivery systems involving few undesirable side effects during administration are based on novel triphasic estrogen/progestogen combinations, wherein the amount of estrogen is increased stepwise over the three phases.
    Type: Grant
    Filed: April 20, 1989
    Date of Patent: October 9, 1990
    Assignee: Warner-Lambert Company
    Inventor: Roger M. Boissonneault
  • Patent number: 4956355
    Abstract: Compounds of the general Formula (I) ##STR1## in which R is a hydrogen atom or a bromine atom, and R.sub.1 is a hydrogen atom, an SO.sub.2 OM group wherein M is a hydrogen or sodium atom, various sulphatide or phosphatide groups or a glucuronide group are disclosed for use in the prophylaxis and therapy of retroviral infections, especially infection by Human Immunodeficiency Virus. These compounds may be used concomitantly or in combination with various immunomodulators and/or antiviral agents.
    Type: Grant
    Filed: April 15, 1988
    Date of Patent: September 11, 1990
    Assignee: Colthurst Limited
    Inventor: Patrick T. Prendergast
  • Patent number: 4956357
    Abstract: Disclosed is synthesized dihydrotestosterone heptanoate, its method of synthesis, and its method of use as an androgenic hormone of male gynecomastia, as a hormonal probe, as well as other applications.
    Type: Grant
    Filed: March 28, 1986
    Date of Patent: September 11, 1990
    Inventors: Bruce S. Keenan, James T. Sparrow
  • Patent number: 4954490
    Abstract: A 11.beta.-aryl-19-norprogesterone steroid of the formula: ##STR1## wherein (i) R.sup.1 is H, C.sub.1-4 alkyl, C.sub.2-4 alkenyl, C.sub.2-4 alkynyl, OH, OC(O)CH.sub.3, or OC(O)R.sup.5, wherein R.sup.5 is C.sub.2-8 alkyl, C.sub.2-8 alkenyl, C.sub.2-8 alkynyl or aryl, R.sub.2 is H, R.sup.3 is H, C.sub.1-4 alkyl, C.sub.2-4 alkenyl or C.sub.2-4 alkynyl, R.sup.4 is H, CH.sub.3, F or Cl, R.sup.6 is H, (CH.sub.3).sub.2 N, CH.sub.3 O, CH.sub.3 CO, CH.sub.3 S, CH.sub.3 SO, CH.sub.3 SO.sub.2, and X is O or NOCH.sub.3 ; or(ii) R.sup.1 and R.sup.2 taken together are a carbon-carbon bond and R.sup.3, R.sup.4, R.sup.6 and X are as defined above; or(iii) R.sup.1 and R.sup.3 taken together are --CH.sub.2 -- or --N.dbd.N--CH.sub.2 --, R.sup.2 is H and R.sup.4, R.sup.6 and X are as defined above; or(iv) R.sup.2 and R.sup.3 taken together are .dbd.CH.sub.2 and R.sup.1, R.sup.4, R.sup.6 and X are as defined above.
    Type: Grant
    Filed: June 23, 1988
    Date of Patent: September 4, 1990
    Assignee: Research Triangle Institute
    Inventors: C. Edgar Cook, Mansukh C. Wani, Y.-W Lee, Jerry R. Reel, Douglas Rector
  • Patent number: 4954488
    Abstract: The present invention is directed to a method for the treatment of hyperaldosteronism and related disorders which comprises administering to an appropriate patient an appropriate 17.beta.-cyclopropylaminoandrostene.
    Type: Grant
    Filed: June 14, 1989
    Date of Patent: September 4, 1990
    Assignee: Merrell Dow Pharmaceuticals Inc.
    Inventor: J. O'Neal Johnston
  • Patent number: 4952586
    Abstract: A composition is provided which includes a balanced combination of an edrophonium component and an atropine component. A preferred embodiment has 0.5 mg of edrophonium chloride and 8 micrograms of atropine sulfate, with respect to patient weight. The inventive composition is useful to antagonize nondepolarizing blockade during medical treatment when muscle relaxation is no longer necessary, provides extremely rapid onset of action and results in minimal heart rate changes.
    Type: Grant
    Filed: October 18, 1988
    Date of Patent: August 28, 1990
    Assignee: The Regents of the University of California
    Inventors: Robert B. Morris, Roy Cronnelly, Ronald Dean Miller
  • Patent number: RE33364
    Abstract: The present invention discloses a process for the production of androsta-4,9(11)-diene-3,17-dione type compounds from 9.alpha.-hydroxyandrostenedione type compounds by non-aromatic oxygenated strong acid dehydration.
    Type: Grant
    Filed: April 14, 1988
    Date of Patent: October 2, 1990
    Assignee: The Upjohn Company
    Inventors: John M. Beaton, Joel E. Huber, Amphlett G. Padilla, Max E. Breuer